<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00462644</url>
  </required_header>
  <id_info>
    <org_study_id>05-050</org_study_id>
    <nct_id>NCT00462644</nct_id>
  </id_info>
  <brief_title>Evaluation of Etomidate on Adrenal Function in Trauma Patients</brief_title>
  <official_title>A Single Dose of Etomidate During Rapid Sequence Induction in Trauma Patients Causes Significant Adrenocortical Insufficiency: A Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tennessee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tennessee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trauma patients are at increased risk for adrenal function insufficiency. A commonly used
      agent for rapid sequence intubation (RSI) is known to decrease adrenal function. We want to
      determine the incidence of adrenocortical insufficiency and its significance during the first
      24 hours of resuscitation following RSI in trauma patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will have two arms. Patients on one arm will be assigned to receive etomidate (0.3
      mg/kg) and succinylcholine (1mg/kg) for RSI. Patients on the other arm will receive standard
      therapy at this institution which consists of Versed (generic name midazolam) (5 mg) plus
      fentanyl (100 mcgs) as well as succinylcholine for RSI. Both drug regimens have a rapid
      onset, short duration and short half-life.

      Patients will be randomly assigned to one arm of the study. The trauma nurse emergency room
      responders, intensive care unit staff, or helicopter crew will pull a study envelope which
      will contain a randomization to either the etomidate arm or standard therapy arm. The numbers
      will correspond to a log, delineating which medication is given. The nurse will document the
      medication as RSI Study Drug - etomidate or RSI Study Drug - standard and the randomization
      packet number (ie, RSI Study Drug, etomidate, #1, RSI Study Drug, standard, #2, etc.) and
      will document the patient's name and medical record number on the study log in either the
      helicopter or the ER Resuscitation Bay.

      Baseline cortisol level will be drawn prior to RSI. An additional cortisol level will be
      drawn 4-6 hours later. Following this level, a cortrosyn stimulation test will be performed
      by giving 0.25 mg cortrosyn IV and rechecking a cortisol level in 60 minutes. Adrenal
      insufficiency will be defined as a baseline cortisol level of &lt;15 or an increase in cortisol
      of &lt;9 after cortrosyn administration. Patients will be monitored for 24 hours for
      hemodynamics, IV fluid administration , and use of vasopressors. Patient will be resuscitated
      to adequate mean arterial blood pressure and urine output. Any patient found to be adrenal
      insufficient will be treated with hydrocortisone 50 mg IV every 6 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cortisol Levels Pre and Post Rapid Sequence Induction and Cortisol Stimulation Test</measure>
    <time_frame>pre RSI, 4-6 hours post RSI, and again 60 mins later following ACTH stimulation test</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postintubation Cortisol (Baseline Cortisol Level)</measure>
    <time_frame>postintubation (baseline cortisol level)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Baseline Cortisol</measure>
    <time_frame>4-6hr after RSI</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cortisol Level 60 Minutes After Cortisol Stimulating Test (CST)</measure>
    <time_frame>60 minutes after administration of cotrosyn</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>time to hospital discharge in days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit (ICU) Length of Stay</measure>
    <time_frame>time from hospital admission to transfer out of ICU to floor bed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator Days</measure>
    <time_frame>time from intubation to extubation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths</measure>
    <time_frame>death in hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Adrenal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Etomidate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl-Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RSI sedation with etomidate/succinylcholine</intervention_name>
    <description>etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV</description>
    <arm_group_label>Etomidate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RSI sedation with fentanyl/midazolam/succinylcholine</intervention_name>
    <description>100 micrograms fentanyl IV, plus 5 mg midazolam IV, plus 1 mg/kg succinylcholine IV</description>
    <arm_group_label>Fentanyl-Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Trauma mechanism of injury

          -  Patient requires rapid sequence induction for ventilatory support

        Exclusion Criteria:

          -  &lt;18 years old

          -  Prisoners

          -  Pregnant women

          -  Patients with a history of adrenal insufficiency

          -  Patients with adrenal trauma documented by CT scan

          -  Patients receiving corticosteroids in the previous year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente A Mejia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erlanger Medical Center</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hildreth AN, Mejia VA, Maxwell RA, Smith PW, Dart BW, Barker DE. Adrenal suppression following a single dose of etomidate for rapid sequence induction: a prospective randomized study. J Trauma. 2008 Sep;65(3):573-9. doi: 10.1097/TA.0b013e31818255e8.</citation>
    <PMID>18784570</PMID>
  </results_reference>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2007</study_first_posted>
  <results_first_submitted>March 4, 2009</results_first_submitted>
  <results_first_submitted_qc>October 10, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 11, 2009</results_first_posted>
  <last_update_submitted>February 17, 2010</last_update_submitted>
  <last_update_submitted_qc>February 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Vicente A. Mejia, MD</name_title>
    <organization>University of Tennessee College of Medicine, Chattanooga</organization>
  </responsible_party>
  <keyword>adrenal insufficiency</keyword>
  <keyword>etomidate</keyword>
  <keyword>rapid sequence induction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Etomidate</mesh_term>
    <mesh_term>Succinylcholine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult trauma patients admitted to Erlanger Health System's Level I trauma center requiring rapid sequence induction were randomized to one of two approved drug treatment regimens.</recruitment_details>
      <pre_assignment_details>72 hour waiver of consent granted by the Institutional Review Board (IRB)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Etomidate</title>
          <description>Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications</description>
        </group>
        <group group_id="P2">
          <title>Fentanyl-Midazolam</title>
          <description>Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etomidate</title>
          <description>Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications</description>
        </group>
        <group group_id="B2">
          <title>Fentanyl-Midazolam</title>
          <description>Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.8" spread="24.5"/>
                    <measurement group_id="B2" value="43.9" spread="19.5"/>
                    <measurement group_id="B3" value="42.6" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cortisol Levels Pre and Post Rapid Sequence Induction and Cortisol Stimulation Test</title>
        <time_frame>pre RSI, 4-6 hours post RSI, and again 60 mins later following ACTH stimulation test</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <description>days from admission to hospital discharge</description>
        <time_frame>time to hospital discharge in days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etomidate</title>
            <description>Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications</description>
          </group>
          <group group_id="O2">
            <title>Fentanyl-Midazolam</title>
            <description>Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>days from admission to hospital discharge</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="9.5"/>
                    <measurement group_id="O2" value="6.4" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Care Unit (ICU) Length of Stay</title>
        <description>ICU length of stay in days</description>
        <time_frame>time from hospital admission to transfer out of ICU to floor bed</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etomidate</title>
            <description>Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications</description>
          </group>
          <group group_id="O2">
            <title>Fentanyl-Midazolam</title>
            <description>Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.</description>
          </group>
        </group_list>
        <measure>
          <title>Intensive Care Unit (ICU) Length of Stay</title>
          <description>ICU length of stay in days</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="7.2"/>
                    <measurement group_id="O2" value="3.0" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator Days</title>
        <time_frame>time from intubation to extubation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etomidate</title>
            <description>Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications</description>
          </group>
          <group group_id="O2">
            <title>Fentanyl-Midazolam</title>
            <description>Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator Days</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="6.5"/>
                    <measurement group_id="O2" value="1.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Postintubation Cortisol (Baseline Cortisol Level)</title>
        <description>cortisol level after randomization and rapid sequence induction</description>
        <time_frame>postintubation (baseline cortisol level)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etomidate</title>
            <description>Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications</description>
          </group>
          <group group_id="O2">
            <title>Fentanyl-Midazolam</title>
            <description>Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.</description>
          </group>
        </group_list>
        <measure>
          <title>Postintubation Cortisol (Baseline Cortisol Level)</title>
          <description>cortisol level after randomization and rapid sequence induction</description>
          <units>micrograms/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" spread="8.4"/>
                    <measurement group_id="O2" value="27.9" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Normality was tested using the Kolmogorow-Smirnov test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Baseline Cortisol</title>
        <description>change from baseline cortisol (drawn prior to RSI) to 2nd cortisol level (4-6hrs after RSI, but before stim test)</description>
        <time_frame>4-6hr after RSI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etomidate</title>
            <description>Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications</description>
          </group>
          <group group_id="O2">
            <title>Fentanyl-Midazolam</title>
            <description>Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline Cortisol</title>
          <description>change from baseline cortisol (drawn prior to RSI) to 2nd cortisol level (4-6hrs after RSI, but before stim test)</description>
          <units>micrograms/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="9.6"/>
                    <measurement group_id="O2" value="1.1" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cortisol Level 60 Minutes After Cortisol Stimulating Test (CST)</title>
        <time_frame>60 minutes after administration of cotrosyn</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etomidate</title>
            <description>Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications</description>
          </group>
          <group group_id="O2">
            <title>Fentanyl-Midazolam</title>
            <description>Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.</description>
          </group>
        </group_list>
        <measure>
          <title>Cortisol Level 60 Minutes After Cortisol Stimulating Test (CST)</title>
          <units>micrograms/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.91" spread="10.4"/>
                    <measurement group_id="O2" value="39.09" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Deaths</title>
        <description>deaths</description>
        <time_frame>death in hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etomidate</title>
            <description>Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications</description>
          </group>
          <group group_id="O2">
            <title>Fentanyl-Midazolam</title>
            <description>Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths</title>
          <description>deaths</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from intubation until hospital discharge</time_frame>
      <desc>Two deaths occurred during hospitalization, but were not due to any study procedures. Deaths were due to trauma injuries sustained in conjunction with pre-existing conditions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Etomidate</title>
          <description>Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications</description>
        </group>
        <group group_id="E2">
          <title>Fentanyl-Midazolam</title>
          <description>Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>deaths occurred during hospitalization, but were not due to any study procedures.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small trial most likely underpowered; large number of exclusions; other limitations discussed in published paper (PMID: 18784570).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Amy N. Hildreth, MD</name_or_title>
      <organization>Wake Forest University, Department of Surgery</organization>
      <email>ahildret@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

